

# Blood stock management and supply for rare blood groups



Willy A. Flegel

Dept Transfusion Medicine, Univ Hospital Ulm

Inst Clin Transfus Medicine & Immunogenetics Ulm

# Observational study

- between May 2000  
and December 2001

## TRANSFUSION COMPLICATIONS

---

**Antibodies to high-frequency antigens may decrease the quality of  
transfusion support: an observational study**

*Axel Seltsam, Franz F. Wagner, Abdulgabar Salama, and Willy A. Flegel*

**TRANSFUSION 2003;43:1563-1566.**

- Presentation at SVTM meeting
- Berne, Switzerland 3 Sept 2004

# Background

- high-frequency antigens
  - > 99 %
- immunized patients are rare
- blood donors are also rare
  - spontaneously detected after immunization only
  - then, they often cannot donate blood
- difficult supply
  - compatible red cell units are rare
- significant diligence and costs required
  - search
  - storage
  - transport logistics
- physicians are often inexperienced in special needs of such patients

# Rationale

- documentation of demand
  - prerequisite for financing and support
    - of donor typing programs
    - of frozen red cell programs
- documentation of clinical relevance
  - current hemovigilance systems do often not cover adverse affects caused by insufficient supply

# Aim of the study

- evaluation of the current supply situation
- in all hospitalized patients
  - carrying clinically relevant allo-antibodies
  - directed against high frequency antigens (excluding k)
- current supply situation
  - population in Central Europe
    - ca. 100 Mio. inhabitants
  - survey period
    - 20 months

# Data acquisition

- written request to
  - all blood centers
  - all immunhematology reference laboratories
- asking for spontaneous reporting
- in A – CH – D
- standardized questionnaire
- follow up
  - until discharge from hospital
- regular contact
  - by phone/mail/Email

# Patients

- total of 52 patients
- with 56 hospital admissions
- minimal estimate
- incidence: 0.04 per 100,000 inhabitants and year

**TABLE 3. Antibody specificities**

Antibody specificity	Number of cases observed
anti-Kp <sup>b</sup>	11
anti-Vel	10
anti-Lu <sup>b</sup>	8
anti-Yt <sup>a</sup>	8
anti-Co <sup>a</sup>	3
anti-H	3
anti-AnWj	2
anti-Kx	2
anti-MAM	2
anti-Fy <sup>ab</sup>	1
anti-Ku	1
anti-Lan	1
anti-Lu8	1
anti-LW <sup>a</sup>	1
anti-Rh17	1
anti-Tj <sup>a</sup> (PP1Pk)	1
Total	56

# Antibody specificities

- 4 antibody specificities
  - Kp<sup>b</sup>
  - Vel
  - Lu<sup>b</sup>
  - Yt<sup>a</sup>

TABLE 3. Antibody specificities	
Antibody specificity	Number of cases observed
anti-Kp <sup>b</sup>	11
anti-Vel	10
anti-Lu <sup>b</sup>	8
anti-Yt <sup>a</sup>	8
anti-Co <sup>a</sup>	2
anti-H	3
anti-AnWj	2
anti-Kx	2
anti-MAM	2
anti-Fy <sup>ab</sup>	1
anti-Ku	1
anti-Lan	1
anti-Lu8	1
anti-LW <sup>a</sup>	1
anti-Rh17	1
anti-Tj <sup>a</sup> (PP1Pk)	1
Total	56

66 %

- in two third of all reported patients



# Transfusions

- 133 compatible red cell units
  - supplied
  - for 26 patients
- thereof, 104 red cell units
  - transfused
  - in 22 patients
- transfusion of red cell units in D:
  - relationship
  - rare red cell units to all red cell units
- 1 : 68,000

# Deviations from protocol

- 23 x reported
  - 9 x no reason for deviation communicated
- reasons
  - reported in 14 patients
  - considered acceptable in 9 patients
- in 5 patients avoidable

TABLE 2. Support strategies by country

	Number of episodes			
	Germany	Switzerland	Austria	Total
Episodes of hospitalization	42	11	3	56
Deviations from protocol	18	3	2	23
Frozen allogeneic units				
Supplied	74	0	0	74
Transfused	62	0	0	62
Fresh allogeneic units				
Supplied	25	12	0	37
Transfused	19	8	0	27
Fresh autologous units				
Supplied	18	4	0	22
Transfused	11	4	0	15

# Reasons for deviation

- compatible supply not considered (n = 3)
- avoidable delay in antibody identification (n = 1)
- no cost coverage for rare blood units
  - but erythropoietin administered (n = 1)

**TABLE 1. Deviations from standard transfusion policy in patients with antibodies to high-frequency antigens**

Type of deviation from protocol	Number of episodes				Antibodies involved*
	Germany	Switzerland	Austria	Total	
No compatible blood as backup†					
Surgery	5	1	0	6	anti-Kp <sup>b</sup> (n = 2), anti-Yt <sup>a</sup> (n = 2) anti-Lu <sup>b</sup> , anti-AnWj
Diagnostic procedure	1	0	1	2	anti-LW <sup>a</sup> , anti-Fy3
Vaginal delivery	2	0	0	2	anti-Kp <sup>b</sup> , anti-Vel
Transfusion of antigen-positive units					
Emergency transfusion‡	3	0	0	3	anti-Vel (n = 2), anti-Lu <sup>b</sup>
Elective transfusion	3	2	0	5	anti-Yt <sup>a</sup> (n = 3), anti-Kp <sup>b</sup> , anti-Lu <sup>b</sup>
Transfusions cancelled or limited	4	0	0	4	anti-Vel (n = 2), anti-Co <sup>a</sup> (n = 2)
Diagnostic procedure cancelled	0	0	1	1	anti-Lu8
<b>Total</b>	<b>18</b>	<b>3</b>	<b>2</b>	<b>23</b>	

\* n = 1 unless otherwise indicated.

† No transfusions performed.

‡ Lack of time to obtain compatible units made deviation inevitable.

# Frozen red cell units

- significant differences in the supply strategy

- in D: frozen red cell units are available in various regions
- in CH: more antigen negative donors are known/available

TABLE 2. Support strategies by country				
	Number of episodes			
	Germany	Switzerland	Austria	Total
Episodes of hospitalization	42	11	3	56
Deviations from protocol	18	3	2	23
Frozen allogeneic units				
Supplied	74	0	0	74
Transfused	62	0	0	62
Fresh allogeneic units				
Supplied	25	12	0	37
Transfused	19	8	0	27
Fresh autologous units				
Supplied	18	4	0	22
Transfused	11	4	0	15

- no effect on the safety of the supply

# International supply

- urgent demand in 14 patients
- 11 x national
  - within one day in most cases
  - mean 1.5 days
  - range 1 – 3 days
- 3 x international
  - mean 2.3 days
  - range 2 – 3 days
- mean supply period was 0.8 days longer
  - for imported red cells units

# Possible supply of compatible red cell units

- 3.3 Mio. donations per year in D 1998
- correlates to
  - 5,000 Lu<sup>b</sup> neg.
  - 5,000 Yt<sup>a</sup> neg.
  - 830 Vel neg.
  - 330 Kp<sup>b</sup> neg.
- permanent availability of red cell units
  - 560 Lu<sup>b</sup> neg.
  - 560 Yt<sup>a</sup> neg.
  - 90 Vel neg.
  - 35 Kp<sup>b</sup> neg.
- considering shelf life of 5 – 6 weeks

# Conclusions

- insufficient supply  
in 33 % of the affected patients
- two third of cases  
require 4 antibody specificities only
- supply would be improved by
  - systematic screening for Kp<sup>b</sup>, Vel, Lu<sup>b</sup>, Yt<sup>a</sup> neg.
  - enhanced awareness of the attending physicians
- optimal supply would require < 1 : 10.000  
red cell units of the whole national stocks

# ISBT Rare Donor Working Party

## International Society for Blood Transfusion


- BR – Brasil
- CN – China
- DE – Germany
- FR – France
- GB - England
- IN - India
- IS - Israel
- JP - Japan
- NL – Netherlands
- NZ – New Zealand
- SA – South Africa
- USA
- Chair: Graeme Woodfield, Auckland NZ
- ca. 14 members
- <http://www.isbt-web.org/>



# European Frozen Blood Bank, Amsterdam


## Council of Europe Bloodbank

- supply in France and England self-sufficient
- supplies 60 – 100 frozen red cells per year to the remaining European countries
  - „fraction of supply to Germany has been diminishing“ (telephone communication)
- **4.925 Euro per unit plus transport**
  - „does not cover actual costs“ (tel. communication)
- actual stock of frozen units
  - [http://www.sanquin.nl/sanquin-eng/sqn\\_home\\_eng.nsf](http://www.sanquin.nl/sanquin-eng/sqn_home_eng.nsf)



- 5 participating institutions in D & CH:
  - Baden-Baden, Berlin, Bern, Hagen, Ulm

# Website of the SRK Bern



- <http://rare.bsd-be.ch>



- kindly provided by H. Hustinx

Seltene Spender | Schweiz | 17.02.2003 - Microsoft Internet Explorer - BSD SRK Bern

# http://rare.bsd-be.ch

Zurück Vorwärts Abbrechen Aktualisieren Startseite Suchen Favoriten Verlauf E-Mail Drucken

Adresse <http://rare.bsd-be.ch/switzerland/> Wechseln zu Links

BSZ	Sp-Nr.	ABO	Rh	Rh.-PhTyp	Cw	M	N	S	s	P1	Lua	Lub	K	k	Kpa	Kpb	Lea	Leb	Fya	Fyb	Jka	Jkb	Xga	Coa	Cob	Besonderes
BE	1457459	O	+	CcD.ee	-	+	+	+	+	+	-	+	-	+	+	-	-	+	+	+	+	-				K mod
SG	191552	A	neg	ccddee		-	+	-	+	+	-	+	-	+	+	-	-	+	+	-	+	-				Kp(b) neg
BE	1762440	O	+	ccD.Ee	-	+	+	-	+	+	-	+	-	+	+	-	-	+	+	+	+	+				Kp(b) neg
BE	1451764	O	+	CcD.ee	-	+	+	+	-	+	-	+	-	+	+	-	+	-	+	+	+	+				Kp(b) neg
BE	1760775	O	+	CcD.ee	-	+	+	-	+	+	-	+	-	+	+	-	-	+	+	+	+	-				Kp(b) neg
BE	1569177	O	+	ccD.Ee	-	+	-	-	+	-	-	+	-	+	+	-	-	+	-	+	+	-				Kp(b) neg
LS	115254	O	+	CCD.ee	-	-	+	-	+	+	-	+	-	+	+	-	+	-	-	+	+	+				Kp(b) neg
BE	1573292	O	neg	ccddee	-	+	+	-	+	+	-	+	-	+	+	-	-	+	+	+	-	+				Kp(b) neg
Zü	339665	O	neg	ccddee		+	-	-	+	+	-	+	-	+	+	-	+	-	+	+	+	+				Kp(b) neg
LS	165802	O	neg	ccddee	-	+	+	-	+	+	-	+	-	+	+	-	-	+	-	+	-	+				Kp(b) neg
BE	1459984	A	+	CcD.ee	-	+	+	-	+	+	+	+	-	+	+	-	-	+	+	+	+	+				Kp(b) neg

« < > » Kell Cellano Lutheran Vel Rhesus Rhesus R2R2 Pk Colton Kidd LAN Yt(a) andere Syst.


Fertig Internet

Start Posteingang - Microsoft O... Seltene Spender | Sc...

01:52



- kindly provided by H. Hustinx

# Seltene Blutgruppen



<http://www.uni-ulm.de/~wflegel/RARE/>

# Webpage statistics July 2004



<http://www.uni-ulm.de/~wflegel/RARE/> **IKT ulm**

# SCARF Homepage





# „Local Exchange Net“

- DGTI Working Party  
„German Rare Donor Program“
- Organization of the Local Exchange Net  
Dr. M. Tilmann, Berlin
- current participants
  - Ahrens, Böhlen-Bodmer, Endres, Flegel, Förstemann, Glameyer, Hustinx, Ladewig, Lonicer, Petershofen, Scharberg, Seltsam, Sternberger, Tilmann, Wagner/München, Wagner/Springe, Zimmermann

# Concluding remark

Only the systematic screening among donors will prevent shortages in the supply of red cell units with rare blood groups.